作者:U. Pleiss、D. Seidel、R. Grosser
DOI:10.1002/jlcr.1103
日期:2006.10.15
distribution, metabolism and excretion (ADME studies). The BAY 59-7939 was labeled with carbon-14 in the carboxamide group in one step in an overall radiochemical yield of 85% starting from 4-4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}mor-pholin-3-one and 5-chlorothiophene-2-[14C]carboxylic acid. The radiolabeled metabolite M-4 was prepared in 77% yield starting from [1-14C]glycine and 5-ch
BAY 59-7939 是一种新型的、口服的、直接的 Xa 因子抑制剂,用于预防和治疗血栓栓塞性疾病的临床开发。药物吸收、分布、代谢和排泄(ADME 研究)需要放射性标记的 BAY 59-7939。BAY 59-7939 从 4-4-[(5S)-5-(氨基甲基)-2-oxo-1, 3-恶唑烷-3-基]苯基}吗啉-3-酮和5-氯噻吩-2-[14C]羧酸。从 [1-14C] 甘氨酸和 5-氯噻吩-5-羧酸开始,以 77% 的产率制备了放射性标记的代谢物 M-4。版权所有 © 2006 John Wiley & Sons, Ltd.